BI Shanghai Renews Pact With Sinopharm To Quadruple China Sales
This article was originally published in PharmAsia News
Boehringer Ingelheim's China arm renewed its lucrative distribution agreement with Sinopharm Medicine Holding. Boehringer Ingelheim Shanghai Pharmaceuticals said its Chinese sales are expected to more than quadruple in the period between 2006, the year before the agreement was initiated, and 2012. In 2007, BI Shanghai signed a one-year agreement giving Sinopharm its first distribution deal with a foreign company, while making BI the first foreign drug maker to give a Chinese company full distribution rights for all of its products. The renewal extends the agreement through the end of 2009. (Click here for more
You may also be interested in...
Procter & Gamble, through its UK wellness subsidiary Nature's Best, is on-trend with new vegan vitamin D3 and iron supplements. Nature's Best has also launched three other vitamin D3 products in the country, as well as an ashwagandha supplement.
The MHRA has updated its guidance on regulatory flexibilities for medical devices and medicinal products resulting from COVID-19 to highlight how its approach differs from the EU.
The Swiss company is planning a US trial of CBSO, the first transcatheter septal occluder with a bioresorbable, metal-free frame.